7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine
View Patent ↗The compound having the structural formula I or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.
1. A method of treating Parkinson's Disease, Extra-Pyramidal Syndrome, dystonia, akathisia, pseudoparkinsonism, tardive dyskinesia, restless legs syndrome, essential tremor, Huntington's Disease, attention deficit hyperactivity disorder, Alzheimer's Disease, negative symptoms of schizophrenia, depression, stroke or psychoses with a compound of the formula
or a pharmaceutically acceptable salt thereof.
2. A method of claim 1 for treating Parkinson's Disease, Extra-Pyramidal Syndrome, restless legs syndrome or attention deficit hyperactivity disorder.
3. A method of treating Parkinson's Disease comprising administering to a mammal in need of such treatment an effective amount of a combination of the compound of the formula
or a pharmaceutically acceptable salt thereof, and 1 to 3 other agents useful in treating Parkinson's Disease.
4. The method of claim 3 wherein the other agents are selected from the group consisting of L-DOPA, dopaminergic agonists, MAO-B inhibitors, DOPA decarboxylase inhibitors and COMT inhibitors.
5. The method of claim 1 for treating or preventing Extra-Pyramidal Syndrome.
6. The method of claim 5 wherein the Extra-Pyramidal Syndrome has been caused by treatment with a typical antipsychotic agent or an atypical antipsychotic agent.
7. The method of claim 6 wherein the typical antipsychotic agent is selected from the group consisting of loxapine, haloperidol, chlorpromazine, prochlorperazine and thiothixene, and the atypical antipsychotic agent is selected from the group consisting of clozapine, olanzapine, loxapine, quetiapine, ziprasidone, risperidone and aripiprazole.
8. The method of claim 5 further comprising administering an antipsychotic agent.
9. The method of claim 8 wherein the antipsychotic agent is a typical antipsychotic agent selected from the group consisting of loxapine, haloperidol, chlorpromazine, prochlorperazine and thiothixene, or an atypical antipsychotic agent selected from the group consisting of clozapine, olanzapine, loxapine, quetiapine, ziprasidone, risperidone and aripiprazole.
10. A method of claim 1 for the treatment of idiopathic dystonia or dystonia caused by the use of cocaine.
11. The method of claim 1 for the treatment or prevention of dystonia caused by treatment with a tricyclic antidepressant, lithium or an anticonvulsant.
12. The method of claim 11 further comprising administering a tricyclic antidepressant, lithium or an anticonvulsant.
13. The method of claim 12 wherein the tricyclic antidepressant is selected from the group consisting of perphenazine, amitriptyline, desipramine, doxepin, trimipramine and protriptyline, and the anticonvulsant is selected from the group consisting of phenytoin, carbamazepine and gabapentin.
14. A method of treating restless leg syndrome or periodic leg movement in sleep comprising administering a therapeutically effective amount of a compound of the formula
or a pharmaceutically acceptable salt thereof to a patient in need thereof.
15. The method of claim 11 further comprising administering levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, a benzodiazepine, an opioid, an anticonvulsant or iron.